ProQR Therapeutics
543 Bryant Street
Palo Alto
California
94301
United States
Website: https://proqr-tx.com/
Email: info@proqr-tx.com
About ProQR Therapeutics
We are ProQR, a biotechnology company dedicated to changing lives by developing RNA therapies for rare genetic diseases. We focus our drug development mainly on a group of blinding disorders affecting the retina, called inherited retinal diseases.
138 articles about ProQR Therapeutics
-
ProQR Therapeutics B.V. Announces R&D Day In New York On June 15
5/9/2017
-
ProQR Therapeutics B.V. Announces Clearance Of IND Application To Start Clinical Trial For QR-110 In Leber’s Congenital Amaurosis Type 10 Patients
4/27/2017
-
ProQR Therapeutics B.V. Announces Annual Meeting Of Shareholders
4/10/2017
-
ProQR Therapeutics B.V. Announces The Grant Of Two Key Patents, Protecting QR-010 For Cystic Fibrosis In The U.S. And EU
4/3/2017
-
ProQR Therapeutics B.V. Appoints David M. Rodman, MD As Chief Development Strategy Officer
3/27/2017
-
ProQR Therapeutics B.V. Announces Results For The Fourth Quarter And Full Year 2016 And Provides A Business Update
2/28/2017
-
On A Shared Quest To Find Treatments For Rare Diseases, ProQR Therapeutics B.V. Supports Rare Disease Day
2/27/2017
-
ProQR Therapeutics B.V. Announces Results For The Third Quarter Of 2016
11/14/2016
-
ProQR Therapeutics B.V. Announces That QR-010 Meets The Primary Endpoint In A Proof Of Concept Study Of Homozygous F508del Cystic Fibrosis Patients
10/27/2016
-
ProQR Therapeutics B.V. Announces Clinical Data Presentations And Investor & Analyst Event At NACFC
9/27/2016
-
ProQR Therapeutics B.V. To Present At Scientific And Investor Conferences In September
9/6/2016
-
ProQR Therapeutics B.V. Announces Results For The Second Quarter Of 2016
8/17/2016
-
ProQR Therapeutics B.V. Receives Fast Track Designation From FDA For QR-010 For Cystic Fibrosis
7/19/2016
-
ProQR Therapeutics B.V. To Release Topline Data From Proof Of Concept Study Of QR-010 In Cystic Fibrosis Patients At NACFC
6/21/2016
-
ProQR Therapeutics B.V.’s Drug Candidate QR-110 For Leber’s Congenital Amaurosis Type 10 Receives European Medicines Agency And FDA Orphan Drug Designation
6/1/2016
-
ProQR Therapeutics B.V. Announces Presentations At The European CF Conference And The JMP Life Science Conference
6/1/2016
-
ProQR Therapeutics B.V. Announces Results For The First Quarter Of 2016
5/18/2016
-
ProQR Therapeutics B.V. Announces Annual Meeting Of Shareholders
4/7/2016
-
ProQR Therapeutics B.V. To Highlight A Growing Pipeline During A Research & Development Day And Present At The Barclays Global Healthcare Conference
3/1/2016
-
ProQR Therapeutics B.V. Announces Results For The Fourth Quarter And Full Year 2015
2/17/2016